Phase I Orally Administered 14C-AZD2171 in Patients With Solid Metastatic Tumors

A Phase 1, Open Label, Non-Randomised, Single Centre Pharmacokinetic and Mass Balance Study of Orally Administered 14-C-AZD2171 in Patients With Solid Metastatic Tumours

Open, non-randomised, radiolabelled, single centre study with a total of six patients with solid metastatic tumors to determine the rates and routes of elimination of 14C-AZD2171 and its metabolites.

Inclusion Criteria:

• histologically confirmed metastatic tumor which is refractory to standard therapies
• life expectancy is 12 weeks or longer
• WHO performance status is 0-12

Exclusion Criteria:

• radiotherapy and chemotherapy within 4 weeks before the start of the study treatment
• patients with a history of poorly controlled hypertension
• history or evidence of any medical condition that might affect gastrointestinal function
• patients that have participated in a radiolabelled study in the last 5 years